Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117

Leukemia
D HaaseB Wörmann

Abstract

It has been supposed in de novo AML that malignant transformation occurs at the level of committed progenitors. Recent data of our group and others provide evidence that in AML malignant transformation may regularly occur at the level of stem cells. These cells can be discriminated by function and specific surface molecules. CD34, a glycophosphoprotein, is a cellular surface antigen characteristically expressed by stem cells. CD34+ stem cells can be further subdivided by the expression of additional surface molecules like CD38 and CD117. In this article we present results from cytogenetic examinations of FACS-isolated stem cell subpopulations in eight patients (four AML and four MDS). Six of them displayed clonal karyotype abnormalities at the time of first diagnoses in the native bone marrow (5q-; 5q- and complex abnormalities; +8; inv(16) and +8; i(17q) and -21; i(21q)). We used CD117, the receptor for the stem cell factor (also KIT oncogene) as a new cellular surface marker. CD34+/CD117+/- stem cell subpopulations were examined in two patients with AML and three patients with MDS. We found leukemic stem cells in every type of stem cell subpopulation examined (CD34+/CD38-, CD34+/CD38+, CD34+/CD117-, CD34+/CD117+). Secondary, ...Continue Reading

Citations

Apr 1, 1995·Annals of Hematology·D HaaseE Lengfelder
Nov 15, 2002·International Journal of Hematology·Hisamaru Hirai
Mar 30, 2000·Leukemia Research·D UçkanA M Tuncer
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Ritter
Jan 14, 2000·Critical Reviews in Oncology/hematology·J F San MiguelJ J van Dongen
Jun 22, 2013·Leukemia·J SchanzD Haase
Feb 11, 2014·Best Practice & Research. Clinical Haematology·Aristoteles Giagounidis, Detlef Haase
Dec 18, 2013·Oncogene·H K EliasU Steidl
Apr 3, 2004·British Journal of Haematology·Francesco BuccisanoValter Gattei
Nov 22, 2007·European Journal of Haematology·Francesco BuccisanoAdriano Venditti
May 4, 2004·Cancer Genetics and Cytogenetics·Jeanna Welborn
Jul 28, 2005·Leukemia Research·Patricia DisperatiRichard A Wells
Jul 26, 2005·Leukemia Research·Christian SteidlDetlef Haase
Aug 12, 2008·Seminars in Oncology·Wai-In Chan, Brian J P Huntly
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie SchanzDetlef Haase
Apr 16, 2016·Nature Communications·Dongmei CaoWeiping J Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.